Chennai Meenakshi Multispeciality Hospital Ltd vs Nephrocare Health Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 33.15 as of 30 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Nephrocare Health Services Ltd changed from 66 on March 2026 to 66 on March 2026 . This represents a CAGR of 0.00% over 1 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Nephrocare Health Services Ltd changed from ₹ 5072 crore on March 2026 to ₹ 5072 crore on March 2026 . This represents a CAGR of 0.00% over 1 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Nephrocare Health Services Ltd for the Jun '26 is ₹ 289.21 crore as compare to the Mar '26 revenue of ₹ 277.18 crore. This represent the growth of 4.34% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Nephrocare Health Services Ltd for the Jun '26 is ₹ 67.78 crore as compare to the Mar '26 ebitda of ₹ 62.24 crore. This represent the growth of 8.9% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Nephrocare Health Services Ltd changed from ₹ 20.11 crore to ₹ 31.97 crore over 7 quarters. This represents a CAGR of 30.33% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Nephrocare Health Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About Nephrocare Health Services Ltd

Nephrocare Health Services Limited was incorporated as 'Nephrocare Health Services Private Limited', a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company was converted into a public limited company and the name was changed to 'Nephrocare Health Services Limited' with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy.
The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad.
It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd.

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Nephrocare Health Services Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 24 Cr while Market cap of Nephrocare Health Services Ltd is 6,193 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd?

As of November 1, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹33.15. On the other hand, Nephrocare Health Services Ltd stock price is INR ₹615.95.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Nephrocare Health Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.